SE445174B - Farmaceutisk komposition innehallande en cyklosporin och en berarsubstans - Google Patents
Farmaceutisk komposition innehallande en cyklosporin och en berarsubstansInfo
- Publication number
- SE445174B SE445174B SE7901683A SE7901683A SE445174B SE 445174 B SE445174 B SE 445174B SE 7901683 A SE7901683 A SE 7901683A SE 7901683 A SE7901683 A SE 7901683A SE 445174 B SE445174 B SE 445174B
- Authority
- SE
- Sweden
- Prior art keywords
- cyclosporin
- weight
- parts
- composition according
- oil
- Prior art date
Links
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title claims description 24
- 108010036949 Cyclosporine Proteins 0.000 title claims description 24
- 229960001265 ciclosporin Drugs 0.000 title claims description 24
- 229930105110 Cyclosporin A Natural products 0.000 title claims description 22
- 229930182912 cyclosporin Natural products 0.000 title claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 4
- 239000000126 substance Substances 0.000 title claims description 4
- 239000000203 mixture Substances 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000003921 oil Substances 0.000 claims description 4
- 235000019198 oils Nutrition 0.000 claims description 4
- 239000002285 corn oil Substances 0.000 claims description 3
- 235000005687 corn oil Nutrition 0.000 claims description 3
- 108010040786 dihydrocyclosporin C Proteins 0.000 claims description 3
- 239000004006 olive oil Substances 0.000 claims description 3
- 235000008390 olive oil Nutrition 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 239000008158 vegetable oil Substances 0.000 claims description 2
- 238000005809 transesterification reaction Methods 0.000 claims 2
- 240000007817 Olea europaea Species 0.000 claims 1
- 229920001515 polyalkylene glycol Polymers 0.000 claims 1
- 150000002148 esters Chemical class 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 108010036941 Cyclosporins Proteins 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 235000019489 Almond oil Nutrition 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241001149960 Tolypocladium inflatum Species 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/27—Cyclic peptide or cyclic protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Description
7901683-8
... w
w _
van?
ä På
2 »SW
Fä _
fl/ \ val?
(iso-cyklosporin D)
_
w
2 zí
mlmlwL
F".
2 wßw
u whm \ _
m\ u w mß
(cyklosporin A)
(dihydro-cyklosporin C)
10
15
20
25
30
35
7901683-8
l:
Cyklosporin A, dihydrocyklosporin C och isocyklosporin D är de föredragna
cyklosporinerna.
De under a) angivna icke-joniska estrarna kan framställas på i och för sig
i känt sätt, t.ex. som beskrivs i US-PS 3 288 824. Estrarna kan vara transesteri-
fieringsprodukter av tvâ moldelar av en naturlig olja, såsom majsolja, mandelolja,
jordnötsolja, olivolja och/eller palmolja, med en moldel polyetylenglykol med en
molekylvikt på 200 till 800. Sådana estrar finns i handeln under namnet
LABRAFIL (se Fiedler, Lexikon der Hilfstoffe, sid. 320, 1971) och framställs
exempelvis av Lab. Gattefosse, Boulogne sur Seine, Franrike. Den föredragna
- estern får man ur omättad naturlig olja; föredragen är exempelvis en triglycer-
idoleat-polyetylen-blandning, som finns i handeln under namnet LABRAFIL M
191m CS.
Den föredragna totalkoncentrationen av komponenterna liksom vikt~
förhållandet mellan de enskilda komponenterna beror bl.a. på de speciellt
använda komponenterna och särskilt på deras löslighetseffekt och även på den
använda cyklosporinen och cyklosporinens koncentration i den slutgiltiga kom-
positionen.
I allmänhet använder man per lO viktdelar av komponent a) 0,2 till 10
delar av cyklosporinen, särskilt l till 10 delar av cyklosporinen och företrädesvis
I till 7 delar av cyklosporinen.
Viktandelen etanol kan exempelvis uppgå till 2 till 596 för parenterala
kompositioner och l till 20% för kompositioner för oral tillförsel, i vardera fallet
räknat pä hela kompositionen.
Viktandelen av växtoljan kan exempelvis uppgå till 35 till 6096 räknat på
totalkompositionen.
Om en av komponenterna är fast vid rumstemperatur, skall man för
framställning av kompositionerna använda temperaturer upp till ca 70°C för att
få en flytande smälta, i vilken den aktiva substansen kan lösas. Därefter kyls
kompositionerna, varefter de exempelvis mals.
Komponenterna b) och c) kan t.ex. vara närvarande i koncentrationer upp
till 60% av totalkompositionen för att man skall uppnå en tillfredsställande
koncentration av cyklosporinen.
Egenskaperna hos kompositionen enligt uppfinningen kan bestämmas på i
och för sig känt sätt. Lösningarnas stabilitet, särskilt mot utkristallisation av den
aktiva substansen, kan fastställas med användning av kända tester. Fördragbar-
heten för tillförselformerna kan fastställas enligt kända fördragbarhetstester.
Absorptionen av cyklosporinerna, särskilt det snabba inträdandet av en
tillfredsställande koncentration av cyklosporinen-i blodet och den höga totalab-
sorptionen av cyklosporinen under 21+ timmar, fastställs med användning av
lO
15
20
25
30
35
7901683-8
standardtester.
Vid ett test tillförs en farmaceutisk komposition enligt föreliggande
uppfinning till kaniner, råttor, hundar eller rhesusapor oral t, intramuskulärt eller
subkutant i en dos av 2-600 mg av cyklosporinen per kg djurvikt. Blodserumprov
och urinprov tas med regelbundna tidsintervall, exempelvis varje timme, och den
däri ingående peptidkoncentrationen bestäms på i och för sig känt sätt.
Den farmakodynamiska aktiviteten för cyklosporinen kan bestämmas påi
och för sig känt sätt. I fallet cyklosporin A kan peptidens verkan fastställas
genom hämning av lymfocytproliferationen. För detta uppsamlas blodserumet
med regelbundna tidsintervall efter tillförsel av substansen och tillsätts i en
koncentration av 0,3 till 10% in vitro till en mjältcellsuspenson från mus, där
lymfocytproliferationen utlöses genom concanavalin A under en 72 timmars
odlingsperiod. BH-tymidin tillsätts sedan och efter 24 timmar mäts tymidinin-
byggnaden för bestämning av lymfocytproliferationen.
Om så önskas kan peptiden tillföras i radioaktiv form. Exempelvis kan
man i ett experiment tillföra l00 mg BH-märkt cyklosporin A (framställt genom
fermentering av den kända svampstammen Tolypocladium inflatum Gams NRRL
8044 i närvaro av metionin märkt med tritium i SCHB-gruppen), som befinner sig
i en farmaceutisk komposition enligt föreliggande uppfinning, oralt i form av en
dricklösning eller en kapsel, eller intramuskulärt i form av en injektionslösning
till Beagle-hundar av hankön. Blodprov tas från varje hund var 15:e minut efter
tillförseln upp till en timme efter tillförseln och sedan varje timme upp till 8
timmar efter tillförseln. Urinen uppsamlas likaså. Bestämning av radioaktivite-
ten i blodet och i urinen anger peptidabsorptionen.
Mängden av den cyklosporin som skall tillföras i den farmaceutiska
kompositionen enligt föreliggande uppfinning beror givetvis på tillförselsättet,
den önskade effekten och behandlingsbetingelserna.
l allmänhet kommer andelen av den med hjälp av den farmaceutiska
kompositionen enligt föreliggande uppfinning tillförda cyklosporinen att vara av
samma storleksordning som den cyklosporin som tillförs på något annat sätt.
De mängder som erfordras för att man skall uppnå en terapeutisk verkan
är kända. Om man använder kompositioner enligt föreliggande uppfinning, skall
en daglig dos av 3 mg/kg till 50 mg/kg cyklosporiner tillföras för behandling av
kroniska inflammationer och för att man skall uppnå en immunosuppressiv effekt.
Det efterföljande exemplet beskriver uppfinningen.
Exempel: Dricklösning
200 mg cyklosporin A löses direkt under omrörning i l ml blandning av
"Labrafil M 191m CS" och etanol (i förhållandet 40:15) vid ZSOC, och efter tillsats
Claims (7)
10 15 20 25 30 7901683-8 6 av 0,1; ml olivolja eller majsolja filtreras den erhållna lösningen och fylls på små flaskor. Lösningen innehåller per 10 víktdelar "Labrafil" 3 viktdelar cyklosporin A, 3 viktdelar etanol och 5 viktdelar oliv- eller majsolja. PATENTKRAV l. Farmaceutisk komposition innehållande en cyklosporin och en bärar- substans, k ä n n e t e ck n a d av att bärarsubstansen består av följande komponenter: a) en icke-jonisk transesterífieringsprodukt av en oljetriglycerid och en polyalkylenglykol, b) en växtol ja, och c) etanol.
2. Komposítion enligt patentkravet l, k ä n n e t e c k n a d av att cyklosporinen är cyklosporin A och/eller dihydro- cyklosporin C och/eller isocyklosporin D.
3. Komposition enligt patentkravet 1, k ä n n e t e c k n a d av att den under a) angivna komponenten erhållits genom omíörestring av två moldelar naturlig olja med en moldel polyetylenglykol med en molekylvikt från 200 till 800.
4. Komposition enligt något av de föregående patentkraven, k ä n n e t e c k n a d av att den per 10 viktdelar av komponenten a) innehåller 0,2 till l0 delar cyklosporin.
5. Komposition enligt något av de föregående patentkraven, k å n n e t e c k n a d av att den innehåller komponenterna b) och c) tillsammans i en viktandel upp till 60% med avseende på hela kombinationen.
6. i Komposition enligtnågot av de föregående patentkraven, k ä n n e t e c k n a d av att den innehåller komponenten b) i en viktandel från 35 till 60% med avseende på hela kombinationen.
7. Komposition enligt något av de föregående patentkraven, k ä n n e t e c k n a d av att den innehåller komponenten c) i en viktandel från l till 2096 med avseende på hela kombinationen.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH246178A CH636013A5 (en) | 1978-03-07 | 1978-03-07 | More readily absorbable pharmaceutical composition |
| CH863478 | 1978-08-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE7901683L SE7901683L (sv) | 1979-09-08 |
| SE445174B true SE445174B (sv) | 1986-06-09 |
Family
ID=25690510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE7901683A SE445174B (sv) | 1978-03-07 | 1979-02-26 | Farmaceutisk komposition innehallande en cyklosporin och en berarsubstans |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US4388307A (sv) |
| JP (1) | JPS54132223A (sv) |
| AR (1) | AR223667A1 (sv) |
| AT (1) | AT375828B (sv) |
| AU (1) | AU528714B2 (sv) |
| CA (1) | CA1139667A (sv) |
| CY (1) | CY1285A (sv) |
| DD (1) | DD142149A5 (sv) |
| DE (1) | DE2907460A1 (sv) |
| DK (1) | DK154539C (sv) |
| ES (1) | ES478295A1 (sv) |
| FI (1) | FI65914C (sv) |
| FR (1) | FR2419072A1 (sv) |
| GB (1) | GB2015339B (sv) |
| HK (1) | HK48585A (sv) |
| IE (1) | IE48016B1 (sv) |
| IL (1) | IL56790A (sv) |
| IT (1) | IT1115038B (sv) |
| KE (1) | KE3516A (sv) |
| MY (1) | MY8500134A (sv) |
| NL (2) | NL187260C (sv) |
| NO (2) | NO152635C (sv) |
| NZ (1) | NZ189819A (sv) |
| PH (1) | PH15159A (sv) |
| PT (1) | PT69309A (sv) |
| SE (1) | SE445174B (sv) |
| SG (1) | SG14785G (sv) |
Families Citing this family (159)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE43335T1 (de) * | 1980-02-14 | 1989-06-15 | Sandoz Ag | Peptide die einen (1s,2r,3r)- oder (1r,2s,3s)-1nitrilo-1-carbonyl-3-methyl-2-oxyheptan oder hept-5-en-rest enthalten brauchbar in totaler synsthese von cyclosporinen, und verfahren zu ihrer herstellung. |
| DE3224619A1 (de) * | 1981-07-14 | 1983-05-19 | Freund Industrial Co., Ltd., Tokyo | Orale pharmazeutische zusammensetzung |
| US4525339A (en) * | 1982-10-15 | 1985-06-25 | Hoffmann-La Roche Inc. | Enteric coated oral dosage form |
| EP0127426A1 (en) * | 1983-05-23 | 1984-12-05 | Takeda Chemical Industries, Ltd. | Percutaneous pharmaceutical compositions for external use |
| US5639724A (en) | 1984-07-24 | 1997-06-17 | Sandoz Ltd. | Cyclosporin galenic forms |
| GB8903804D0 (en) * | 1989-02-20 | 1989-04-05 | Sandoz Ltd | Improvements in or relating to organic compounds |
| US5411951A (en) * | 1984-10-04 | 1995-05-02 | Monsanto Company | Prolonged release of biologically active somatotropin |
| US5474980A (en) * | 1984-10-04 | 1995-12-12 | Monsanto Company | Prolonged release of biologically active somatotropins |
| US4727035A (en) * | 1984-11-14 | 1988-02-23 | Mahoney Walter C | Immunoassay for cyclosporin |
| US4576645A (en) * | 1984-12-06 | 1986-03-18 | Block Drug Co., Inc. | Whipped gel composition |
| JPS61280435A (ja) * | 1985-04-04 | 1986-12-11 | Kanji Takada | サイクロスポリン類のリンパ指向性製剤 |
| US4775659A (en) * | 1985-08-19 | 1988-10-04 | Eli Lilly And Company | Injectable semi-solid formulations |
| GB8524421D0 (en) * | 1985-10-03 | 1985-11-06 | Boots Co Plc | Therapeutic agents |
| US4764381A (en) * | 1985-12-06 | 1988-08-16 | Key Pharmaceuticals, Inc. | Percutaneous penetration enhancer of oleic acid and 2-ethyl-1, 3-hexanediol |
| US5118493A (en) * | 1986-05-02 | 1992-06-02 | Brigham And Women's Hospital | Composition having reduced nephrotoxocity comprising a fatty acid containing component and cyclosporine |
| ATE80295T1 (de) * | 1986-05-02 | 1992-09-15 | Brigham & Womens Hospital | Fettsaeure und cyclosporin enthaltende zusammensetzung mit ermaessigter nephrotoxizitaet. |
| KR880012221A (ko) * | 1987-04-13 | 1988-11-26 | 사노 가즈오 | 에스테르 또는 아미드를 활성성분으로 함유하는 약제 조성물 |
| JP2577049B2 (ja) * | 1987-06-04 | 1997-01-29 | 三共株式会社 | シクロスポリン製剤 |
| GB8717300D0 (en) * | 1987-07-22 | 1987-08-26 | Nat Res Dev | Cyclosporins |
| WO1989001772A1 (en) * | 1987-09-03 | 1989-03-09 | University Of Georgia Research Foundation, Inc. | Ocular cyclosporin composition |
| US4839342A (en) * | 1987-09-03 | 1989-06-13 | University Of Georgia Research Foundation, Inc. | Method of increasing tear production by topical administration of cyclosporin |
| AU620048B2 (en) * | 1987-09-03 | 1992-02-13 | University Of Georgia Research Foundation, Inc., The | Ocular cyclosporin composition |
| US5756450A (en) * | 1987-09-15 | 1998-05-26 | Novartis Corporation | Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms |
| DE3830494B4 (de) * | 1987-09-15 | 2006-05-18 | Novartis Ag | Wasserlösliche Monoester als Solubilisatoren für pharmakologische Wirkstoffe und pharmazeutische Hilfsstoffe |
| HU205010B (en) * | 1987-09-15 | 1992-03-30 | Sandoz Ag | Process for producing pharmaceutical compositions comprising compounds soluble up to 1 per cent and having medical activity |
| EP0327280B1 (en) * | 1988-01-29 | 1992-03-18 | Sankyo Company Limited | Cyclosporin compositions |
| CH679119A5 (sv) * | 1988-05-13 | 1991-12-31 | Sandoz Ag | |
| HU201567B (en) * | 1988-07-21 | 1990-11-28 | Gyogyszerkutato Intezet | Process for production of intravenous medical compositions containing cyclosphorin |
| KR0148748B1 (ko) * | 1988-09-16 | 1998-08-17 | 장 크라메르, 한스 루돌프 하우스 | 사이클로스포린을 함유하는 약학조성물 |
| US6007840A (en) * | 1988-09-16 | 1999-12-28 | Novartis Ag | Pharmaceutical compositions comprising cyclosporins |
| US5342625A (en) * | 1988-09-16 | 1994-08-30 | Sandoz Ltd. | Pharmaceutical compositions comprising cyclosporins |
| GR1000466B (el) * | 1989-01-28 | 1992-07-30 | Sandoz Ag | Μεθοδος παρασκευης νεων φαρμακευτικων μορφων κυκλοσπορινης. |
| GB2230440B (en) * | 1989-02-09 | 1993-05-19 | Sandoz Ltd | Novel cyclosporin galenic forms |
| US7081445B2 (en) | 1989-02-20 | 2006-07-25 | Novartis Ag | Cyclosporin galenic forms |
| US5540931A (en) * | 1989-03-03 | 1996-07-30 | Charles W. Hewitt | Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants |
| US4996193A (en) * | 1989-03-03 | 1991-02-26 | The Regents Of The University Of California | Combined topical and systemic method of administration of cyclosporine |
| HU208491B (en) * | 1990-11-27 | 1993-11-29 | Gyogyszerkutato Intezet | Process for producing oral pharmaceutical composition containing cyclosporin |
| US6262022B1 (en) | 1992-06-25 | 2001-07-17 | Novartis Ag | Pharmaceutical compositions containing cyclosporin as the active agent |
| GB9113872D0 (en) * | 1991-06-27 | 1991-08-14 | Sandoz Ag | Improvements in or relating to organic compounds |
| GB9208712D0 (en) * | 1992-04-22 | 1992-06-10 | Sandoz Ltd | Pharmaceutical compositions containing cyclosporin derivates |
| SG45449A1 (en) | 1992-05-13 | 1998-01-16 | Sandoz Ltd | Ophthalmic compositions |
| US5527537A (en) * | 1992-05-18 | 1996-06-18 | Dietl; Hans | Pharmaceutical preparation containing cyclosporine(s) for intravenous administration and a process for its production |
| US5637317A (en) * | 1992-05-18 | 1997-06-10 | Dietl; Hans | Pharmaceutical preparation containing cyclosporin(s) for oral administration and process for producing same |
| CZ278863B6 (en) * | 1992-09-07 | 1994-07-13 | Galena | Medicinal preparations with n-methylated cyclic undecapeptides |
| DK0589843T3 (da) | 1992-09-25 | 2002-04-02 | Novartis Ag | Cyclosporinholdige farmaceutiske præparater |
| NZ247516A (en) * | 1993-04-28 | 1995-02-24 | Bernard Charles Sherman | Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant |
| CH686761A5 (de) * | 1993-05-27 | 1996-06-28 | Sandoz Ag | Galenische Formulierungen. |
| US20020099067A1 (en) * | 1993-07-08 | 2002-07-25 | Ulrich Posanski | Pharmaceutical compositions for sparingly soluble therapeutic agents |
| EP0649651B1 (en) | 1993-09-28 | 2000-12-13 | R.P. Scherer GmbH | Soft gelatin capsule manufacture |
| DE4340781C3 (de) * | 1993-11-30 | 2000-01-27 | Novartis Ag | Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung |
| KR0146671B1 (ko) * | 1994-02-25 | 1998-08-17 | 김충환 | 사이클로스포린-함유 분말 조성물 |
| NZ270145A (en) * | 1994-03-01 | 1996-08-27 | Lilly Co Eli | Non-aqueous pharmaceutical formulation for oral administration comprising water-insoluble active agent, fatty acid solubilising agent, an oil and a surface active agent |
| JP2936209B2 (ja) * | 1994-06-01 | 1999-08-23 | ユーハン コーポレーション | サイクロスポリン含有組成物およびその製造方法 |
| SE518578C2 (sv) * | 1994-06-15 | 2002-10-29 | Gs Dev Ab | Lipidbaserad komposition |
| CA2195623A1 (en) * | 1994-07-22 | 1996-02-08 | Rajeev D. Gokhale | Self-emulsifying drug delivery system |
| JP3833248B2 (ja) | 1994-11-03 | 2006-10-11 | ノバルティス・アクチエンゲゼルシャフト | 簡単な組成及び高い生物有効性を有する経口投与のためのシクロスポリンの新規処方物及びその製造法 |
| US5603951A (en) * | 1994-11-09 | 1997-02-18 | Hanmi Pharm. Ind. Co., Ltd. | Cyclosporin-containing soft capsule compositions |
| HU215966B (hu) * | 1994-11-21 | 1999-07-28 | BIOGAL Gyógyszergyár Rt. | Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum |
| KR0167613B1 (ko) * | 1994-12-28 | 1999-01-15 | 한스 루돌프 하우스, 니콜 케르커 | 사이클로스포린-함유 연질캅셀제 조성물 |
| KR100239799B1 (ko) * | 1995-01-21 | 2000-02-01 | 손경식 | 경구투여용 사이클로스포린 에이 고체미셀분산체, 이의 제조 방법 및 고형제제 |
| US6696413B2 (en) * | 1995-06-16 | 2004-02-24 | Hexal Ag | Pharmaceutical preparation with cyclosporin A |
| SE504582C2 (sv) * | 1995-07-06 | 1997-03-10 | Gs Dev Ab | Cyklosporinkomposition baserad på en L2-fas |
| JP3009742B2 (ja) * | 1995-08-25 | 2000-02-14 | サングスタット メディカル コーポレイション | 経口用シクロスポリン製剤 |
| US5827822A (en) * | 1996-03-25 | 1998-10-27 | Sangstat Medical Corporation | Cyclosporin a formulations as nanoparticles |
| US5834017A (en) * | 1995-08-25 | 1998-11-10 | Sangstat Medical Corporation | Oral cyclopsporin formulations |
| US5766629A (en) * | 1995-08-25 | 1998-06-16 | Sangstat Medical Corporation | Oral cyclosporin formulations |
| US5962019A (en) * | 1995-08-25 | 1999-10-05 | Sangstat Medical Corporation | Oral cyclosporin formulations |
| RU2172183C2 (ru) * | 1995-08-25 | 2001-08-20 | Сангстат Медикал Корпорейшн | Оральные циклоспориновые составы |
| DE19544507B4 (de) | 1995-11-29 | 2007-11-15 | Novartis Ag | Cyclosporin enthaltende Präparate |
| US5858401A (en) | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
| US5958876A (en) * | 1996-06-19 | 1999-09-28 | Novartis Ag | Cyclosporin-containing pharmaceutical compositions |
| KR980008239A (ko) * | 1996-07-26 | 1998-04-30 | 김충환 | 사이클로스포린-함유 약학적 조성물 |
| US5798333A (en) * | 1996-09-17 | 1998-08-25 | Sherman; Bernard C. | Water-soluble concentrates containing cyclosporins |
| AU737053B2 (en) * | 1997-01-30 | 2001-08-09 | Novartis Ag | Oil-free pharmaceutical compositions containing cyclosporin A |
| CZ301382B6 (cs) * | 1997-03-12 | 2010-02-10 | Abbott Laboratories Chad377/Ap6D-2 | Hydrofilní binární systémy pro podávání cyklosporinu |
| NZ314702A (en) * | 1997-04-29 | 1998-07-28 | Bernard Charles Sherman | Pharmaceutical composition comprising a cyclosporin in a solvent system of acetylated monoglycerides and a surfactant and optionally a hydrophilic solvent |
| US6258783B1 (en) | 1997-04-29 | 2001-07-10 | Bernard Charles Sherman | Emulsion preconcentrate comprising a cyclosporin and acetylated monoglyceride |
| US6346511B1 (en) | 1997-09-08 | 2002-02-12 | Panacea Biotec Limited | Pharmaceutical composition comprising cyclosporin |
| US6187747B1 (en) | 1997-09-08 | 2001-02-13 | Panacea Biotech Limited | Pharmaceutical composition comprising cyclosporin |
| IN188719B (sv) * | 1997-09-08 | 2002-11-02 | Panacea Biotec Ltd | |
| US6008191A (en) * | 1997-09-08 | 1999-12-28 | Panacea Biotec Limited | Pharmaceutical compositions containing cyclosporin |
| US6063762A (en) * | 1997-12-05 | 2000-05-16 | Chong Kun Dang Corp. | Cyclosporin-containing microemulsion preconcentrate composition |
| US6028067A (en) * | 1997-12-05 | 2000-02-22 | Chong Kun Dang Corp. | Cyclosporin-containing microemulsion preconcentrate composition |
| KR19990047897A (ko) * | 1997-12-05 | 1999-07-05 | 김충환 | 사이클로스포린 함유 약학적 조성물 |
| NZ512287A (en) * | 1998-12-11 | 2002-12-20 | Pharmasolutions Inc | Pharmaceutical compositions comprising a lipophilic drug in a propylene glycol ester of a higher fatty acid carrier, where 60% of the ester is a monoester |
| WO2000040219A1 (en) | 1998-12-30 | 2000-07-13 | Dexcel Ltd. | Dispersible concentrate for the delivery of cyclosporin |
| US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| US6761903B2 (en) | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| CN1156461C (zh) * | 1999-03-24 | 2004-07-07 | R·P·希拉技术股份有限公司 | 改良的水溶性药物制剂 |
| US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| US6057289A (en) * | 1999-04-30 | 2000-05-02 | Pharmasolutions, Inc. | Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system |
| US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| US6982281B1 (en) * | 2000-11-17 | 2006-01-03 | Lipocine Inc | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
| US6458383B2 (en) | 1999-08-17 | 2002-10-01 | Lipocine, Inc. | Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin |
| US7732404B2 (en) | 1999-12-30 | 2010-06-08 | Dexcel Ltd | Pro-nanodispersion for the delivery of cyclosporin |
| GB0000313D0 (en) * | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| EP1273287A1 (en) * | 2000-04-04 | 2003-01-08 | Shionogi & Co., Ltd. | Oily compositions containing highly fat-soluble drugs |
| AU6608701A (en) * | 2000-06-21 | 2002-01-02 | Audit Institute For Medical Services And Quality Assurance Gmbh | Pharmaceutical preparations containing cyclosporines and neutral oils |
| SI1333851T1 (sl) * | 2000-09-18 | 2008-02-29 | Rpg Life Sciences Ltd | Sestavek, ki sam po sebi tvori emulzijo, z izboljsanimi bioabsobcijskimi in imunosupresijskimi aktivnostmi |
| HUP0400263A2 (hu) * | 2001-06-21 | 2005-03-29 | Pfizer Products Inc. | Koleszteril-észter transzfer protein inhibitort tartalmazó önemulgeáló készítmény |
| NZ530845A (en) | 2001-07-06 | 2006-03-31 | Sucampo Ag | Composition for topical administration |
| PT1435910E (pt) * | 2001-10-19 | 2009-09-07 | Isotechnika Inc | Novos pré-concentrados de microemulsão de análogos da ciclosporina |
| US20050070468A1 (en) * | 2001-11-21 | 2005-03-31 | Sucampo Ag | Use of fk506 and analogues for treating allergic diseases |
| WO2003053404A1 (en) * | 2001-12-20 | 2003-07-03 | Bernard Charles Sherman | Pharmaceutical compositions comprising a cyclosporin, a hydrophilic surfactant and a lipophilic surfactant |
| KR20030065831A (ko) * | 2002-02-01 | 2003-08-09 | 주식회사 태평양 | 사이클로스포린을 함유한 지속 방출형 약학적 조성물 |
| US6828301B2 (en) * | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
| GB2391471B (en) * | 2002-08-02 | 2005-05-04 | Satishchandra Punambhai Patel | Pharmaceutical compositions |
| GB2391472B (en) * | 2002-08-02 | 2004-12-08 | Satishchandra Punambhai Patel | Pharmaceutical compositions |
| GB2391473B (en) * | 2002-08-02 | 2004-07-07 | Satishchandra Punambhai Patel | Pharmaceutical compositions |
| KR100507771B1 (ko) * | 2002-11-08 | 2005-08-17 | 한미약품 주식회사 | 난용성 감기약 활성 성분의 경구투여용 조성물 및 그의제조 방법 |
| US7842791B2 (en) * | 2002-12-19 | 2010-11-30 | Nancy Jean Britten | Dispersible pharmaceutical compositions |
| US6979672B2 (en) | 2002-12-20 | 2005-12-27 | Polichem, S.A. | Cyclosporin-based pharmaceutical compositions |
| US20040150061A1 (en) * | 2003-01-30 | 2004-08-05 | Hsin Chung Hsien | Package structure of a photosensor |
| EP2359817B1 (en) * | 2003-03-28 | 2018-01-10 | Sigmoid Pharma Limited | Solid oral dosage form containing seamless microcapsules |
| US20050059583A1 (en) | 2003-09-15 | 2005-03-17 | Allergan, Inc. | Methods of providing therapeutic effects using cyclosporin components |
| TW200517114A (en) | 2003-10-15 | 2005-06-01 | Combinatorx Inc | Methods and reagents for the treatment of immunoinflammatory disorders |
| KR20060120208A (ko) | 2003-11-21 | 2006-11-24 | 콤비네이토릭스, 인코포레이티드 | 염증성 질환의 치료 방법 및 시약 |
| DE102004038980A1 (de) * | 2004-08-10 | 2006-02-23 | Cognis Deutschland Gmbh & Co. Kg | Antibeschlagmittel für Kunststoffe |
| EP2153824A1 (en) * | 2004-09-27 | 2010-02-17 | Sigmoid Pharma Limited | Seamless multiparticulate formulations |
| US7151085B2 (en) * | 2004-11-15 | 2006-12-19 | Allergan, Inc. | Therapeutic methods using cyclosporine components |
| US7135455B2 (en) * | 2004-11-15 | 2006-11-14 | Allergan, Inc | Methods for the therapeutic use of cyclosporine components |
| WO2006102157A1 (en) | 2005-03-21 | 2006-09-28 | Ivax Pharmaceuticals S.R.O. | Crystallization inhibitor and its use in gelatin capsules |
| US7297679B2 (en) | 2005-07-13 | 2007-11-20 | Allergan, Inc. | Cyclosporin compositions |
| US7202209B2 (en) | 2005-07-13 | 2007-04-10 | Allergan, Inc. | Cyclosporin compositions |
| US7276476B2 (en) * | 2005-07-13 | 2007-10-02 | Allergan, Inc. | Cyclosporin compositions |
| US7288520B2 (en) | 2005-07-13 | 2007-10-30 | Allergan, Inc. | Cyclosporin compositions |
| US20070015693A1 (en) * | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Cyclosporin compositions |
| US20070015691A1 (en) * | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Cyclosporin compositions |
| US7501393B2 (en) * | 2005-07-27 | 2009-03-10 | Allergan, Inc. | Pharmaceutical compositions comprising cyclosporins |
| US7745400B2 (en) * | 2005-10-14 | 2010-06-29 | Gregg Feinerman | Prevention and treatment of ocular side effects with a cyclosporin |
| US9839667B2 (en) | 2005-10-14 | 2017-12-12 | Allergan, Inc. | Prevention and treatment of ocular side effects with a cyclosporin |
| AU2006311577B2 (en) | 2005-11-09 | 2013-02-07 | Zalicus Inc. | Methods, compositions, and kits for the treatment of medical conditions |
| WO2008122965A2 (en) | 2007-04-04 | 2008-10-16 | Sigmoid Pharma Limited | Pharmaceutical cyclosporin compositions |
| BRPI0811538A2 (pt) * | 2007-05-04 | 2015-08-11 | Allergan Inc | Uso de ciclosporinas no tratamento de pacientes com lentes intraoculares. |
| GB2451811A (en) | 2007-08-09 | 2009-02-18 | Ems Sa | Delivery composition for solubilising water-insoluble pharmaceutical active ingredients |
| TW200932240A (en) * | 2007-10-25 | 2009-08-01 | Astellas Pharma Inc | Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production |
| US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
| BRPI1006826A2 (pt) | 2009-01-08 | 2017-08-15 | Allergan Inc | Composições para melhorar o crescimento de unhas |
| US20110009339A1 (en) * | 2009-04-14 | 2011-01-13 | Allergan, Inc | Method of treating blurred vision and other conditions of the eye with cyclosporin compositions |
| ES2530049T3 (es) | 2009-05-18 | 2015-02-26 | Sigmoid Pharma Limited | Composición que comprende gotas de aceite |
| CN102470103B (zh) | 2009-07-07 | 2016-09-07 | 贝林格尔.英格海姆国际有限公司 | 用作丙型肝炎病毒蛋白酶抑制剂的药物组合物 |
| US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
| EP3556774B1 (en) | 2011-03-11 | 2024-01-03 | Beth Israel Deaconess Medical Center Inc. | Anti-cd40 antibodies and uses thereof |
| WO2013052424A2 (en) | 2011-10-05 | 2013-04-11 | Allergan, Inc. | Compositions for enhancing nail health |
| US20130089508A1 (en) | 2011-10-05 | 2013-04-11 | Allergan, Inc. | Compositions for enhancing nail health |
| GB201319791D0 (en) | 2013-11-08 | 2013-12-25 | Sigmoid Pharma Ltd | Formulations |
| US9498485B2 (en) | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
| US20170246187A1 (en) | 2014-08-28 | 2017-08-31 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
| HUE053624T2 (hu) | 2014-11-07 | 2021-07-28 | Sublimity Therapeutics Ltd | Ciklosporint tartalmazó készítmények |
| US20160361322A1 (en) | 2015-06-15 | 2016-12-15 | Lipocine Inc. | Composition and method for oral delivery of androgen prodrugs |
| KR20250007054A (ko) | 2015-09-04 | 2025-01-13 | 프리마토프 테라퓨틱스 인크. | 인간화 항-cd40 항체 및 그의 용도 |
| WO2017047299A1 (ja) * | 2015-09-15 | 2017-03-23 | 富士フイルム株式会社 | 注射用液剤組成物 |
| US11559530B2 (en) | 2016-11-28 | 2023-01-24 | Lipocine Inc. | Oral testosterone undecanoate therapy |
| EP3824296A4 (en) | 2018-07-20 | 2022-04-27 | Lipocine Inc. | LIVER DISEASE |
| JP7752051B2 (ja) * | 2019-05-24 | 2025-10-09 | デクラ ベテリナリー プロダクツ リミテッド ライアビリティー カンパニー | 長時間作用型注射用製剤およびその使用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1274354A (fr) * | 1956-03-10 | 1961-10-27 | Agents tensio-actifs obtenus à partir de triglycérides et polyéthylène glycol | |
| GB1110875A (en) * | 1964-12-11 | 1968-04-24 | Glaxo Lab Ltd | Compositions containing procaine penicillins |
| FR94740E (fr) * | 1967-10-25 | 1969-10-24 | Rhone Poulenc Sa | Nouveaux cyclopeptides et leur préparation. |
| NL167323C (nl) * | 1970-09-26 | 1981-12-16 | Organon Nv | Werkwijze ter bereiding van een psychofarmacologisch preparaat. |
| ES396746A1 (es) * | 1971-11-06 | 1974-12-01 | Gallardo Antonio Sa | Nuevo procedimiento de fabricacion de suspensiones establesidoneas para antibioticos. |
| CH574247A5 (en) * | 1972-02-17 | 1976-04-15 | Ciba Geigy Ag | Oily, injectable peptide/aluminium alkanoate compsns - - with prolonged duration of activity |
| JPS4891218A (sv) * | 1972-03-06 | 1973-11-28 | ||
| AR207116A1 (es) * | 1973-03-28 | 1976-09-15 | Ciba Geigy Ag | Procedimiento para preparar nuevas dotriacontapeptidoamidas |
| DE2455859C2 (de) * | 1973-12-06 | 1983-12-15 | Sandoz-Patent-GmbH, 7850 Lörrach | Das Antibiotikum Cyclosporin A (S 7481/F-1), seine Herstellung und Verwendung |
| GB1547164A (en) * | 1975-08-14 | 1979-06-06 | Beecham Group Ltd | Veterinary compositions |
| CH614931A5 (sv) * | 1975-11-04 | 1979-12-28 | Sandoz Ag | |
| DE2555481C3 (de) * | 1975-12-10 | 1985-10-03 | Sandoz-Patent-GmbH, 7850 Lörrach | Herstellung stabiler Tropflösungen von hydrierten Ergotalkaloiden |
| DE2819094A1 (de) * | 1977-05-10 | 1978-11-23 | Sandoz Ag | Cyclosporin-derivate, ihre verwendung und herstellung |
-
1979
- 1979-02-26 FI FI790640A patent/FI65914C/fi not_active IP Right Cessation
- 1979-02-26 SE SE7901683A patent/SE445174B/sv not_active IP Right Cessation
- 1979-02-26 DE DE19792907460 patent/DE2907460A1/de active Granted
- 1979-02-27 NO NO790661A patent/NO152635C/no unknown
- 1979-02-27 FR FR7904989A patent/FR2419072A1/fr active Granted
- 1979-02-27 IT IT48152/79A patent/IT1115038B/it active Protection Beyond IP Right Term
- 1979-02-28 DK DK086079A patent/DK154539C/da not_active IP Right Cessation
- 1979-03-02 GB GB7907395A patent/GB2015339B/en not_active Expired
- 1979-03-02 NL NLAANVRAGE7901703,A patent/NL187260C/xx active Protection Beyond IP Right Term
- 1979-03-02 CY CY1285A patent/CY1285A/en unknown
- 1979-03-05 IL IL56790A patent/IL56790A/xx unknown
- 1979-03-05 ES ES478295A patent/ES478295A1/es not_active Expired
- 1979-03-05 AT AT0163779A patent/AT375828B/de not_active IP Right Cessation
- 1979-03-05 PT PT69309A patent/PT69309A/pt unknown
- 1979-03-05 NZ NZ189819A patent/NZ189819A/en unknown
- 1979-03-06 CA CA000322853A patent/CA1139667A/en not_active Expired
- 1979-03-06 AU AU44862/79A patent/AU528714B2/en not_active Expired
- 1979-03-06 PH PH22254A patent/PH15159A/en unknown
- 1979-03-06 DD DD79211409A patent/DD142149A5/de not_active IP Right Cessation
- 1979-03-07 AR AR275732A patent/AR223667A1/es active
- 1979-03-07 JP JP2722879A patent/JPS54132223A/ja active Granted
- 1979-08-08 IE IE704/79A patent/IE48016B1/en not_active IP Right Cessation
-
1982
- 1982-02-09 US US06/347,276 patent/US4388307A/en not_active Expired - Lifetime
-
1985
- 1985-02-27 SG SG147/85A patent/SG14785G/en unknown
- 1985-03-22 KE KE3516A patent/KE3516A/xx unknown
- 1985-06-20 HK HK485/85A patent/HK48585A/xx not_active IP Right Cessation
- 1985-12-30 MY MY134/85A patent/MY8500134A/xx unknown
-
1993
- 1993-07-02 NL NL930135C patent/NL930135I1/nl unknown
-
1994
- 1994-12-28 NO NO1994028C patent/NO1994028I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE445174B (sv) | Farmaceutisk komposition innehallande en cyklosporin och en berarsubstans | |
| Bearn et al. | Metabolic studies in Wilson's disease using Cu64 | |
| KR0170769B1 (ko) | 신규한 사이클로스포린 갈렌 제제 | |
| Murgia et al. | The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients | |
| Borel et al. | The history of the discovery and development of cyclosporine (Sandimmune®) | |
| KR100257841B1 (ko) | 사이클로스포린-함유약학적조성물 | |
| Vine et al. | Cyclosporine: structure, pharmacokinetics, and therapeutic drug monitoring | |
| CN1152876A (zh) | 供局部施用于眼组织的泪腺特异性乳状液 | |
| WO1997034622A1 (en) | Oral cyclosporin formulations | |
| UA34454C2 (uk) | Фармацевтична композиція, що містить як активний компонент похідне циклоспорину | |
| EP3055325A1 (en) | Novel derivative of an insulin analogue | |
| US5580574A (en) | Pharmaceutical composition for transdermal delivery | |
| JP3862273B2 (ja) | 経口投与用シクロスポリン含有新規製剤 | |
| Aoyama et al. | Pharmacokinetics of recombinant human interleukin‐11 (rhIL‐11) in healthy male subjects | |
| WO1995029678A1 (en) | Pharmaceutical composition for transdermal delivery | |
| Bowers et al. | Activity-structure relationships of the thyrotropin releasing hormone | |
| TAKADA et al. | Promotion of the selective lymphatic delivery of cyclosporin A by lipid-surfactant mixed micelles | |
| HU182920B (en) | Process for preparing stable pharmaceutical compositions containing cyclosporin | |
| Venkataramanan et al. | Species-specific cyclosporine metabolism | |
| KR20240163072A (ko) | 폴리옥시에틸렌 구조를 포함하는 유성 성분을 함유하는 화합물 제제 | |
| Wang et al. | Biodegradable microsphere-loaded tacrolimus enhanced the effect on mice islet allograft and reduced the adverse effect on insulin secretion | |
| Lettieri et al. | Effects of competitive red blood cell binding and reduced hematocrit on the blood and plasma levels of [14C] Indapamide in the rat. | |
| BUICE et al. | CYCLOSPORINE DISPOSITION IN THE DOG: COMPARISON OF RADIOIMMUNOASSAY WITH HIGH-PERFORMANCE LIQUID CHROMATOGRAHIC ASSAY AND PHARMACOKINETICS FOLLOWING INTRAVENOUS ADMINISTRATION | |
| Wogensen et al. | Repeated intraperitoneal injections of interleukin 1β induce glucose intolerance in normal rats | |
| FI104363B (sv) | Förbättrande med additiv av inbördes farmakologiska verkningar av immunosuppressanter och interferon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NAL | Patent in force |
Ref document number: 7901683-8 Format of ref document f/p: F |
|
| NUG | Patent has lapsed |
Ref document number: 7901683-8 Format of ref document f/p: F |